Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.625 mg of conjugated equine estrogen Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

NCT00543634
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA, Provera 10 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 7, 2026, 9:58 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789
View directory record Official record
Conditions
Healthy
Interventions
bazedoxifene, bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 64 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 7, 2026, 9:58 PM EDT
Terminated Not applicable Interventional

Study of PET Scans and Serotonin in Hot Flashes Treatment

NCT00249847
View directory record Official record
Conditions
Hot Flashes
Interventions
Paroxetine controlled-release, Conjugated equine estrogen
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Not applicable Interventional Results available

Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy

NCT02691936
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause
Interventions
CO2 fractionated vaginal laser, Estrogens, Conjugated (USP)
Device · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

NCT01070979
View directory record Official record
Conditions
Hormone Replacement Therapy
Interventions
Estradiol acetate, Estradiol, Conjugated equine estrogens
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
32
States / cities
Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 3 Interventional

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

NCT03097120
View directory record Official record
Conditions
Heart Disease
Interventions
0.625 mg of conjugated equine estrogen, 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, placebo tablets
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 2 Interventional

POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease

NCT00234676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Premarin ®
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
Up to 75 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
6
States / cities
Sunnyvale, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710
View directory record Official record
Conditions
Endometrial Hyperplasia, Osteoporosis
Interventions
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 4 Interventional

Estrogen and Perimenopausal Depression

NCT00229450
View directory record Official record
Conditions
Depressive Disorder, Major, Menopause
Interventions
Estrogen
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839
View directory record Official record
Conditions
Nocturnal Vasomotor Symptoms
Interventions
SCE-B, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
17
States / cities
Anaheim, California • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 9:58 PM EDT
Terminated No phase listed Observational

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Oct 7, 2026, 9:58 PM EDT
Completed No phase listed Observational Results available

Study Evaluating Changes In Mammographic Breast Density

NCT00774267
View directory record Official record
Conditions
Osteoporosis
Interventions
BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

NCT00706225
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene and conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 4 Interventional Results available

Investigation of the Effect of the Female Urinary Microbiome on Incontinence

NCT02835846
View directory record Official record
Conditions
Overactive Bladder, Incontinence, Nocturia
Interventions
Estrogen Cream
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 7, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

NCT00474851
View directory record Official record
Conditions
Endometriosis
Interventions
Norethindrone acetate + estrogens, norethindrone acetate + placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 7, 2026, 9:58 PM EDT